Young children with moderate-to-severe atopic dermatitis can be treated safely and effectively with either topical tacrolimus or mild corticosteroids

Area of Science:

• Dermatology
• Pediatrics
• Immunology

Background:

• Atopic dermatitis (AD) is a common skin condition in children.
• Topical corticosteroids are a standard treatment for AD, but concerns exist regarding long-term safety in young children.
• Topical tacrolimus is an alternative treatment option for AD.

Purpose of the Study:

• To compare the efficacy and safety of topical tacrolimus versus topical corticosteroids in young children with moderate-to-severe atopic dermatitis.
• To evaluate treatment outcomes in children with and without signs of early sensitization.

Main Methods:

• An interim analysis of a 3-year randomized open-label study.
• 75 children aged 1-3 years with moderate-to-severe AD were enrolled.
• Patients were treated with either topical tacrolimus or topical corticosteroids.

Main Results:

• Both treatments showed improvement in eczema severity (EASI, IGA), transepidermal water loss (TEWL), and serum total immunoglobulin E (IgE).
• Children with early sensitization at baseline showed significantly greater improvement in TEWL and eczema area with tacrolimus at 12 months.
• No severe adverse effects were reported in either treatment group.

Conclusions:

• Topical tacrolimus may be more beneficial than corticosteroids for children with AD and early sensitization.
• Topical tacrolimus presents a safe and effective alternative for managing moderate-to-severe AD in young children.